Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

Japan

SOUSEIKAI PS Clinic, Hakata, Fukuoka

Medical Corporation Heishinkai OPHAC Hospital, Yodogawa, Osaka

Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo